Acute myoloid leukemia (AML) is an aggressive cancer of the blood and bone marrow. It is the most common form of acute leukemia in adults. The prognosis of patients with mutated AML remains poor due to the frequent occurrence of drug resistance mutations within a few months of treatment, and therefore, new options for treatment are needed.
Our invention

Despite progress in recent years, with several new drugs gaining regulatory approval for the treatment of AML, it is unclear whether single drugs targeting a specific genomic alteration will be sufficient to eradicate disease.

  • Our novel approach to target synergistically both FLT3-kinase and TAF1-bromodomain may potentially eliminate drug-resistant leukemic cells more efficiently.

  • Compounds show high affinity for TAF1 and FLT3 and selectivity among bromodomain and protein kinase families.

  • Compared to other bromodomain-inhibitors, our initial results show an improved toxicity profile of the lead compounds while maintaining potency against haematological cancers.

  • The compounds are patentable and could be further developed into a novel drug candidate.